Kindred Biosciences Releases Positive Results of Pilot Field Study of KIND-010 for the Management of Weight in Cats
SAN FRANCISCO, Jan. 26, 2016 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today released positive results from its pilot field study (KB104P) of KIND-010 for the management of weight in cats. It also announced successful completion of the sample size reassessment of the ongoing pivotal study.
This study was a randomized, single-blind, placebo-controlled study that enrolled 32 cats (16 in the KIND-010 group, 16 in the placebo group). The objective was to demonstrate the effectiveness and safety of KIND-010 for the stimulation of weight gain in cats under clinical conditions. At Week 2, mean weight of cats in the KIND-010 group was 4.32 kg (percent increase from Day 1 was 3.25%) versus 3.98 kg (percent increase from Day 1 was -1.65%) in the placebo group (p=0.0042).
KindredBio also announced that the pivotal effectiveness study (KB105) for KIND-010 for the management of weight loss in cats is over halfway enrolled, ahead of schedule. This randomized, double-blind, placebo-controlled study was concurred upon by FDA and will enroll a minimum of 200 cats (100 KIND-010/100 placebo) to assess the mean percent change in body weight from Day 1 to Week 2. The Company conducted a pre-specified, interim sample-size reassessment once over 100 cats were enrolled and determined that the original sample size does not need to be increased.
Richard Chin, M.D., President and Chief Executive Officer, stated, “We are very pleased to release the positive results from the pilot KIND-010 study and the interim sample-size reassessment. Weight loss in cats is a major unmet medical need, and we look forward to further progress.”
About Kindred Biosciences
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.
SOURCE Kindred Biosciences, Inc.
SAN JOSE, Calif., Jan. 26, 2016 /PRNewswire/ — ProteinSimple®, the Protein Platforms division of Bio-Techne, today announced the launch of its advanced capillary electrophoresis system, Maurice™. The new platform is an expansion of iCE product line for imaged capillary electrophoresis for the quantitative analysis of Identity, Purity, and Heterogeneity profiles of bio-pharmaceuticals.
Since its introduction in 1999, the innovative whole column imaging technology of iCE has simplified the analysis of charge heterogeneity to considerably shorten drug development timelines. This technology is the heart of Maurice, delivering the same high resolution performance with even shorter run times. Beyond that, an added native fluorescence detection mode allows for higher sensitivity. Maurice has the new capability for size-based separation across a broad range of molecules and offers optimized methods for IgG purity analysis.
Maurice features a cartridge for each application, allowing the researchers to easily swap between applications without clean-up steps or a risk of cross-contamination. It offers a simpler workflow from set-up to data analysis to reduce variability. Simply insert the cartridge, place the samples, press start, and walk away. The new ‘Compass for iCE’ software simplifies the batch set-up process, system operation and data analysis. Once the batch is complete, the system cleans the cartridge and tweets the user when it is done.
“Maurice simplifies CE to quickly deliver reproducible data on protein therapeutics,” says Chuck Kummeth, CEO of Bio-Techne. “Bio-Techne develops tools that simplify applications and remove complexity, so that the researchers can focus on their science. Maurice brings a new level of data reproducibility and ease-of-use to the CE market. We are excited to welcome him to ProteinSimple family.”
The platform includes three systems: Maurice C. for quantitative pI and Charge heterogeneity analysis, Maurice S. for IgG purity analysis by CE-SDS and Maurice that does both applications.
Maurice will be unveiled at the WCBP on Jan 26th, 2016 in Washington DC, USA. The Maurice team will be at this conference and at the World Congress on Biologics and Biosimilars, Feb 1-2, 2016 in Berlin, Germany to discuss the new platform. You can learn more about the Maurice system at www.proteinsimple.com/maurice
ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). We’re rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Our wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.
ProteinSimple is now a brand in the Bio-Techne family of brands that includes R&D Systems, Novus Biologicals and Tocris. As a company, Bio-Techne has developed, manufactured and sold biotechnology products, clinical calibrators and controls, and consumables for protein analysis—and now analytical instrumentation and consumables through ProteinSimple. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.
©2016 Bio-Techne. Trademarks mentioned in this press release are the property of the Bio-Techne
A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 35 years, using human genetic information to…
From inVentiv Health – 26 Jan 2016 01:09:48 GMT
– View all San Diego jobs
High Complexity Urinalysis Laboratory seeks a very motivated Bench Scientist. Ideal individual will have experience handling chemicals and/or biological samples and be comfortable with verification and recording of test results. Understanding of basi […
LAB NEEDS CLS GENERALIST FOR HIGH COMPLEXITY TESTING
High Complexity Urinalysis, Genetics, Serum Laboratory seeks a highly motivated Clinical Laboratory Scientist with toxicology experience.
Position: The position involves the review of quality con […
Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe….
From Illumina, Inc. – 25 Jan 2016 23:09:32 GMT
– View all San Diego jobs
Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. All About Us….
From Illumina, Inc. – 25 Jan 2016 23:09:32 GMT
– View all San Diego jobs
SAN DIEGO, Jan. 25, 2016 /PRNewswire/ — Due to the storm-related closure of government offices in the State of Maryland, BioMed Realty Trust, Inc. (NYSE: BMR) announced that it expects that the closing of the acquisition of BioMed Realty by affiliates of Blackstone Real Estate Partners VIII (“Blackstone”) will be delayed until later this week, subject to the satisfaction or waiver of all closing conditions related to the transaction, at which time trading of the Company’s shares on the New York Stock Exchange will cease.
As announced previously, on October 7, 2015 BioMed Realty entered into a definitive agreement with affiliates of Blackstone, under which Blackstone will acquire all outstanding shares of common stock of BioMed Realty for $23.75 per share, plus a per diem amount of approximately $0.003 per share for each day from January 1, 2016 until (but not including) the closing date, in an all-cash transaction valued at approximately $8 billion.
About BioMed Realty Trust
BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 18.9 million rentable square feet. Additional information is available at www.biomedrealty.com. Follow us on Twitter @biomedrealty.
Blackstone is a global leader in real estate investing. Blackstone’s real estate business was founded in 1991 and has approximately $92 billion in investor capital under management. Blackstone’s real estate portfolio includes hotel, office, retail, industrial and residential properties in the US, Europe, Asia and Latin America. Major holdings include Hilton Worldwide, Invitation Homes (single family homes), Logicor (pan-European logistics), SCP (Chinese shopping malls), and prime office buildings in the world’s major cities. Blackstone real estate also operates one of the leading real estate finance platforms, including management of the publicly traded Blackstone Mortgage Trust.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These forward-looking statements include, among other things, statements about the expected timing and completion of the proposed merger with affiliates of Blackstone, the satisfaction or waiver of the conditions to closing in the definitive agreement for the proposed merger with affiliates of Blackstone and the occurrence of any change, effect, event, circumstance, occurrence or state of facts that could give rise to the termination of the merger agreement. Forward-looking statements generally can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “should,” “will,” or similar words intended to identify information that is not historical in nature. These risks and uncertainties include, without limitation: the satisfaction or waiver of the conditions to closing in the definitive agreement for the proposed merger with affiliates of Blackstone; unanticipated difficulties or expenditures relating to the proposed merger with affiliates of Blackstone; potential difficulties in employee retention as a result of the announcement and pendency of the proposed merger with affiliates of Blackstone; legal proceedings that have been, or may be, instituted against the company and others related to the proposed merger with affiliates of Blackstone; general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants’ financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company’s target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company’s investment grade credit ratings with the ratings agencies; failure to manage effectively the company’s growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with tax credits, grants and other subsidies to fund development activities; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company’s domestic operations; risks associated with the company’s investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with security breaches and other disruptions to the company’s information technology networks and related systems; risks associated with the company’s potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company’s dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission (the “SEC”), including BioMed Realty’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statement speaks only as of the date of this communication. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or developments, future events or otherwise.
SOURCE BioMed Realty Trust, Inc.
We are currently looking for a Temporary Accountant to work for a leading San Diego biotechnology company….
From BioPhase Solutions – 25 Jan 2016 20:31:01 GMT
– View all San Diego jobs
InvivoGen is a fast growing and profitable biotech company. Our primary objective is to combine cutting-edge research with our technical expertise to provide the bioresearch community with a wide range of tools that are innovative, high quality, cost […